BTIG lowers Tvardi Therapeutics stock price target to $15 on IPF trial setback
NegativeFinancial Markets

BTIG has lowered its price target for Tvardi Therapeutics to $15 following a setback in their IPF trial. This news is significant as it reflects investor concerns about the company's progress and future potential in treating idiopathic pulmonary fibrosis, which could impact stock performance and investor confidence.
— Curated by the World Pulse Now AI Editorial System